Financial Statements Notes to the Company Financial Statements 1 Fixed asset investments Investments in subsidiaries Shares Loans Total $m $m $m At 1 January 2015 16,186 11,240 27,426 Additions 5,934 5,934 Disposals 3,069 3,069 Capital reimbursement 133 133 Exchange 116 116 Amortisation 5 5 At 31 December 2015 16,053 13,994 30,047 A list of subsidiaries is included on pages 194 and 195.
2 Non-trade creditors 2015 2014 $m $m Amounts due within one year Short-term borrowings 679 1,309 Other creditors 128 150 Amounts owed to Group undertakings 7 8 814 1,467 3 Loans Repayment 2015 2014 dates $m $m Amounts due within one year Interest-bearing loans and borrowings 5.125% Non-callable bond euros 2015 912 912 Amounts due after more than one year Amounts owed to subsidiaries 7.2% Loan US dollars 2023 283 283 Interest-bearing loans and borrowings 5.9% Callable bond US dollars 2017 1,747 1,747 Floating rate notes US dollars 2018 399 1.75% Callable bond US dollars 2018 997 1.95% Callable bond US dollars 2019 997 996 2.375% Callable bond US dollars 2020 1,586 0.875% Non-callable bond euros 2021 812 902 3.375% Callable bond US dollars 2025 1,971 5.75% Non-callable bond pounds sterling 2031 515 540 6.45% Callable bond US dollars 2037 2,719 2,718 4% Callable bond US dollars 2042 986 986 4.375% Callable bond US dollars 2045 976 13,705 7,889 All loans and borrowings are unsecured.
2015 2014 $m $m Loans or instalments thereof are repayable: After five years from balance sheet date 8,262 5,429 From two to five years 3,979 2,743 From one to two years 1,747 Within one year 912 Total unsecured 13,988 9,084 With the exception of the 2018 floating rate notes, all loans are at fixed interest rates.
Accordingly, the fair values of the loans will change as market rates change.
However, since the loans are held at amortised cost, changes in interest rates and the credit rating of the Company do not have any effect on the Companys net assets.
200 AstraZeneca Annual Report and Form 20-F Information 2015 Financial Statements 4 Share capital Details of share capital movements in the year and share option schemes are included in Note 22 to the Group Financial Statements.
5 Contingent liabilities In addition to the matter disclosed below, there are other cases where the Company is named as a party to legal proceedings.
These include the Byetta and Farxiga product liability litigations, each of which are described more fully in Note 27 to the Group Financial Statements.
Foreign Corrupt Practices Act In connection with investigations into anti-bribery and corruption issues in the pharmaceutical industry, AstraZeneca has received inquiries from enforcement agencies, including the DOJ and the SEC, regarding, among other things, sales practices, internal controls, certain distributors and interactions with healthcare providers and other government officials in several countries.
AstraZeneca is co-operating with these inquiries.
AstraZenecas investigation has involved indications of inappropriate conduct in certain countries, including China.
Resolution of these matters could involve the payment of fines and or other remedies.
Other The Company has guaranteed the external borrowing of a subsidiary in the amount of $288m.
6 Statutory and other information The Directors were paid by another Group company in 2015 and 2014.
AstraZeneca Annual Report and Form 20-F Information 2015 201
